Drug Repurposing Overcomes the Gram-Negative Permeability Barrier to Expand the Antibacterial Spectrum of MGB-BP-3

Abstract The outer membrane of Gram-negative bacteria imposes a formidable barrier to antibacterial agents, severely limiting the efficacy of many novel drug candidates. MGB-BP-3, a DNA minor groove binder, exhibits potent activity against Gram-positive bacteria but has shown limited efficacy against Gram-negative pathogens due to this permeability barrier. The Pandemic Response Box (PRB), a curated library of structurally diverse molecules, provides a resource to identify potential resistance-circumventing compounds that can be repurposed as adjuvants. Here, we screened the PRB for synergy with MGB-BP-3 against Gram-negative priority pathogens. While MGB-BP-3 alone showed minimal in vitro activity, combination testing identified 15 hit compounds, with pafuramidine and sulbactam showing the most synergy against Escherichia coli. To prioritize translatability, we substituted these hits with clinically relevant mechanistic analogues pentamidine and ceftazidime, respectively, which both maintained synergistic activity as measured by Fractional Inhibitory Concentration Indices (FICI < 0.5). Quantitative confocal microscopy using a fluorescent analogue of MGB-BP-3 (S-MGB-245) confirmed that this potentiation was correlated with increased intracellular accumulation of the S-MGB. In vivo efficacy testing using Escherichia coli-infected Galleria mellonella larvae demonstrated significantly improved larval survival with combination therapy compared to monotherapies (p < 0.05). Notably, coadministering subtherapeutic doses of MGB-BP-3 (12.5 mg/kg) with pentamidine (60 mg/kg) or ceftazidime (0.8 mg/kg) achieved ≥75% survival, whereas these exact same concentrations yielded complete mortality when administered individually. These results highlight the potential of clinically used drugs to overcome the intrinsic resistance of Gram-negative bacteria to MGB-BP-3 by compromising the cell envelope, thereby extending the antibacterial spectrum of MGB-BP-3.

Authors

Institutions

Publication Details

Journal
ACS Infectious Diseases
Published
2026-11-14
DOI
https://doi.org/10.1021/acsinfecdis.6c00855
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Drug Repurposing Overcomes the Gram-Negative Permeability Barrier to Expand the Antibacterial Spectrum of MGB-BP-3

Fraser J. Scott, Liam M. Rooney, Kaveh Eskandari, Louise C Young et al.
1 links
ACS Infectious Diseases
Antibiotic Resistance in Bacteria
article

Drug Repurposing Overcomes the Gram-Negative Permeability Barrier to Expand the Antibacterial Spectrum of MGB-BP-3

Fraser J. Scott, Liam M. Rooney, Kaveh Eskandari, Louise C Young, Douglas Robinson, Katarína Oravcová, Max Caplin
article en

Abstract

Abstract The outer membrane of Gram-negative bacteria imposes a formidable barrier to antibacterial agents, severely limiting the efficacy of many novel drug candidates. MGB-BP-3, a DNA minor groove binder, exhibits potent activity against Gram-positive bacteria but has shown limited efficacy against Gram-negative pathogens due to this permeability barrier. The Pandemic Response Box (PRB), a curated library of structurally diverse molecules, provides a resource to identify potential resistance-circumventing compounds that can be repurposed as adjuvants. Here, we screened the PRB for synergy with MGB-BP-3 against Gram-negative priority pathogens. While MGB-BP-3 alone showed minimal in vitro activity, combination testing identified 15 hit compounds, with pafuramidine and sulbactam showing the most synergy against Escherichia coli. To prioritize translatability, we substituted these hits with clinically relevant mechanistic analogues pentamidine and ceftazidime, respectively, which both maintained synergistic activity as measured by Fractional Inhibitory Concentration Indices (FICI < 0.5). Quantitative confocal microscopy using a fluorescent analogue of MGB-BP-3 (S-MGB-245) confirmed that this potentiation was correlated with increased intracellular accumulation of the S-MGB. In vivo efficacy testing using Escherichia coli-infected Galleria mellonella larvae demonstrated significantly improved larval survival with combination therapy compared to monotherapies (p < 0.05). Notably, coadministering subtherapeutic doses of MGB-BP-3 (12.5 mg/kg) with pentamidine (60 mg/kg) or ceftazidime (0.8 mg/kg) achieved ≥75% survival, whereas these exact same concentrations yielded complete mortality when administered individually. These results highlight the potential of clinically used drugs to overcome the intrinsic resistance of Gram-negative bacteria to MGB-BP-3 by compromising the cell envelope, thereby extending the antibacterial spectrum of MGB-BP-3.

ACS Infectious Diseases
University of Strathclyde (GB), University of Glasgow (GB)
Good health and well-being
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon